Sk Biopharmaceuticals Co Ltd Asset Resilience Ratio

Latest as of March 2026: 0.14%

Sk Biopharmaceuticals Co Ltd asset resilience ratio. Sk Biopharmaceuticals Co Ltd (326030) has an Asset Resilience Ratio of 0.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 326030 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩1.87 Billion
≈ $1.27 Million USD Cash + Short-term Investments

Total Assets

₩1.32 Trillion
≈ $894.83 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Sk Biopharmaceuticals Co Ltd (2016–2025)

Asset resilience ratio of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. This chart shows how Sk Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Read Sk Biopharmaceuticals Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Sk Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Sk Biopharmaceuticals Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩1.87 Billion 0.14%
Total Liquid Assets ₩1.87 Billion 0.14%

Asset Resilience Insights

  • Limited Liquidity: Sk Biopharmaceuticals Co Ltd maintains only 0.14% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Sk Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Sk Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Sk Biopharmaceuticals Co Ltd Asset Resilience Ratio by Year (2016–2025)

Sk Biopharmaceuticals Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sk Biopharmaceuticals Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.14% ₩1.71 Billion
≈ $1.16 Million
₩1.20 Trillion
≈ $812.08 Million
-0.02pp
2024-12-31 0.16% ₩1.68 Billion
≈ $1.14 Million
₩1.04 Trillion
≈ $702.63 Million
-0.03pp
2023-12-31 0.20% ₩1.42 Billion
≈ $961.23K
₩723.17 Billion
≈ $490.08 Million
-30.12pp
2022-12-31 30.32% ₩201.39 Billion
≈ $136.48 Million
₩664.24 Billion
≈ $450.15 Million
+13.48pp
2021-12-31 16.84% ₩108.42 Billion
≈ $73.47 Million
₩643.65 Billion
≈ $436.19 Million
-48.86pp
2020-12-31 65.70% ₩328.66 Billion
≈ $222.73 Million
₩500.24 Billion
≈ $339.01 Million
+43.24pp
2019-12-31 22.46% ₩31.23 Billion
≈ $21.17 Million
₩139.07 Billion
≈ $94.25 Million
+20.12pp
2018-12-31 2.34% ₩2.24 Billion
≈ $1.52 Million
₩95.54 Billion
≈ $64.74 Million
-37.39pp
2017-12-31 39.73% ₩39.08 Billion
≈ $26.48 Million
₩98.37 Billion
≈ $66.66 Million
-27.41pp
2016-12-31 67.14% ₩130.18 Billion
≈ $88.22 Million
₩193.89 Billion
≈ $131.40 Million
--
pp = percentage points

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology
Market Cap
$4.12 Billion
₩6.08 Trillion KRW
Market Cap Rank
#3915 Global
#83 in Korea
Share Price
₩77700.00
Change (1 day)
-0.13%
52-Week Range
₩69400.00 - ₩140700.00
All Time High
₩217000.00
About

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more